Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT07589387

Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3

Conditions: Diabete Mellitus

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 2800
Sponsor: Washington University School of Medicine

Location: New Township Abaji Abaji

Summary

The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.

Eligibility Criteria

Inclusion Criteria: * Aim 3 Inclusion Criteria: Patients will be screened for diabetes with symptoms of hyperglycemia or BMI \>25 kg/m2 and over the age of 18 years old. Upon first or previous diagnosis, diabetes patients will be registered. * Adults (≥18 years), * Patients with previous diabetes diagnosis * Patients with persistently elevated random glucose \>200 mg/dl, fasting glucose \>126 mg/dl, or hemoglobin A1c \>6.5% on two or more occasions (when available) * Patients taking glucose lowering medications * Pregnant women are eligible for this program, or * Cognitively impaired adults are eligible for this program. Exclusion Criteria: * \- This program will not include any of the following special populations: * Individuals who are not yet adults (minors): i.e. infants, children, or teenagers \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07589387). StuddyBuddy aggregates publicly available trial information.